Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.
Liquidia Corporation (LQDA) is a biopharmaceutical innovator leveraging its proprietary PRINT® Technology to develop precision therapies for pulmonary hypertension and rare cardiopulmonary conditions. This page aggregates official company announcements, providing stakeholders with timely updates on clinical advancements, regulatory milestones, and strategic initiatives.
Investors and researchers will find curated press releases detailing progress in Liquidia’s pipeline, including YUTREPIA™ inhalation powder development, FDA communications, and technology licensing agreements. Content spans clinical trial results, manufacturing updates, and partnership announcements with global pharmaceutical entities.
Key categories include treatment efficacy studies, regulatory filings, intellectual property developments, and operational expansions. All materials adhere to factual reporting standards, ensuring reliable insights into the company’s scientific and business trajectory.
Bookmark this page for streamlined access to Liquidia’s latest verified updates. Combine regular visits with professional financial counsel to inform your investment strategy.
Liquidia Corporation (NASDAQ: LQDA) granted a stock option for 2,000 shares of its common stock to a newly hired non-executive employee, as part of the 2022 Inducement Plan. This option, exercisable at $4.58 per share, aligns with Nasdaq Listing Rule 5635(c)(4) regarding inducements for new hires. The stock option vests over four years, with 25% vesting on the first anniversary and the remainder vesting monthly. Liquidia focuses on developing treatments for pulmonary hypertension using its PRINT® Technology.
Liquidia Corporation (NASDAQ: LQDA) announced the appointment of Dr. Rajeev Saggar as Chief Medical Officer, effective July 18, 2022. Dr. Saggar, an expert in pulmonary diseases, will lead the company's research and regulatory affairs, assisting in the anticipated launch of YUTREPIA™, an inhalation powder for pulmonary arterial hypertension, pending final FDA approval. CEO Roger Jeffs highlighted Dr. Saggar’s extensive experience in clinical development and patient care as vital for Liquidia's growth trajectory. This leadership change is expected to enhance the development of innovative therapies.
Liquidia Corporation (NASDAQ: LQDA) recently presented data on the investigational use of YUTREPIA™ (treprostinil) inhalation powder at the Pulmonary Hypertension Association (PHA) International Conference in Atlanta from June 9-11, 2022. The research focused on Quality of Life (QoL) improvements for pulmonary arterial hypertension (PAH) patients, emphasizing the positive impact of YUTREPIA in both new treatments and transitions from other therapies. The FDA previously issued a tentative approval for YUTREPIA on November 5, 2021, which aims to enhance exercise ability for patients with NYHA Functional Class II-III symptoms.
Liquidia Corporation (NASDAQ: LQDA) has announced its participation in the Jefferies Healthcare Conference, where CFO Michael Kaseta will engage in a fireside chat on June 9, 2022, at 8:00 am ET. The conference runs from June 8 to 10, 2022, in New York City. Investors can access a live webcast of the event on Liquidia’s website, which will be archived for 30 days after the conference.
Liquidia focuses on developing products for pulmonary hypertension using its PRINT® Technology, including its inhalation powder YUTREPIA™ for treating pulmonary arterial hypertension.
MORRISVILLE, N.C., June 2, 2022 - Liquidia Corporation (NASDAQ: LQDA) announced that CFO Michael Kaseta will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 11:00 am ET. The event runs from June 8-10, 2022, in New York City. A webcast will be available on Liquidia's investor website and archived for 30 days. Liquidia focuses on developing treatments for pulmonary hypertension, including YUTREPIA™ inhalation powder for PAH.
Liquidia Corporation (NASDAQ: LQDA) announced the presentation of data on YUTREPIA™ (treprostinil) inhalation powder at the ATS International Conference 2022 in San Francisco. The research, focusing on safety and tolerability in treating pulmonary arterial hypertension (PAH), was presented by Dr. Nicholas P. Hill from Tufts Medical Center. YUTREPIA, an investigational drug, has FDA tentative approval aimed at improving exercise ability in adults with NYHA Functional Class II-III symptoms. The company emphasizes its proprietary PRINT® technology used in the drug's development.
Liquidia Corporation (LQDA) reported its Q1 2022 financial results, showing revenue growth to $3.5 million, up from $3.1 million year-over-year. The company secured $53.7 million from a stock offering and increased its credit facility, enhancing its financial position for the anticipated launch of YUTREPIA™. Key corporate actions include advancing its Hatch-Waxman litigation for YUTREPIA approval and bolstering the utilization of Treprostinil Injection amid payer mandates. However, the net loss widened to $15.9 million, compared to $9.2 million in Q1 2021, reflecting higher administrative expenses.
Liquidia Corporation (NASDAQ: LQDA) will report its first quarter 2022 financial results on May 12, 2022. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update. Investors can access the call by dialing 1-877-707-8711 domestically or 1-857-270-6219 internationally, using conference code 4798065. The webcast will be archived for 30 days. Liquidia focuses on pulmonary hypertension treatments using its PRINT® Technology and has developed YUTREPIA™ for pulmonary arterial hypertension.
Liquidia Corporation (NASDAQ: LQDA) announced the grant of stock options for 35,700 shares to newly hired non-executive employees under its 2022 Inducement Plan. Each stock option, granted as a material inducement for employment acceptance, has an exercise price of $5.63 per share, reflecting the closing price on April 22, 2022. These options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) aimed at attracting talent to support Liquidia's growth in pulmonary hypertension treatments.
Liquidia Corporation (NASDAQ: LQDA) announced that Dr. Sandeep Sahay will present clinical data on YUTREPIA™ (treprostinil) inhalation powder at the 42nd Annual Meeting of the International Society for Heart and Lung Transplant in Boston. The presentation titled 'Risk Assessment in Pulmonary Arterial Hypertension (PAH): Insights from the INSPIRE Study' will occur on April 27, 2022. YUTREPIA, a treatment for PAH, received tentative FDA approval on November 5, 2021, aimed at improving exercise ability in adults with specific symptoms.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
